Skip to main content
Top
Published in: Diabetologia 11/2005

01-11-2005 | Editorial

Latent autoimmune diabetes in adults: a guide for the perplexed

Author: E. A. M. Gale

Published in: Diabetologia | Issue 11/2005

Login to get access

Excerpt

Diabetes rejoices in silly names. Maturity-onset diabetes of the young (MODY) is no doubt the silliest, but—for reasons that will emerge—latent autoimmune diabetes in adults (LADA) comes close. There is, however, one important difference between the two conditions: MODY can be defined at a molecular level and LADA is hard to define at all. LADA, as discussed in this issue of Diabetologia [1], exists somewhere in the borderland between type 1 and type 2 diabetes, and exemplifies the difficulties we have in telling the two conditions apart. From a historical perspective, it is easy to see how these difficulties arose. Idiopathic diabetes was long considered a single disease, despite mounting evidence of heterogeneity. Once formulated, however, the concept of two major disorders with distinct phenotypes, genetic determinants and aetiology won almost immediate acceptance [2] and now rules our thinking, just as the one-disease concept did in the past. For this reason it is rarely acknowledged that the methods we use are of limited value in telling the two conditions apart [3]. …
Literature
2.
go back to reference Gale EAM (2001) The discovery of type 1 diabetes. Diabetes 50:217–226PubMed Gale EAM (2001) The discovery of type 1 diabetes. Diabetes 50:217–226PubMed
3.
go back to reference Wilson RM, Van der Minne P, Deverill I et al (1985) Insulin dependence: problems with the classification of 100 consecutive patients. Diabet Med 2:167–172PubMed Wilson RM, Van der Minne P, Deverill I et al (1985) Insulin dependence: problems with the classification of 100 consecutive patients. Diabet Med 2:167–172PubMed
4.
go back to reference Green A, Hougaard P (1983) Epidemiological studies of diabetes mellitus in Denmark: 4. Clinical characteristics of insulin-treated diabetes. Diabetologia 25:231–234CrossRefPubMed Green A, Hougaard P (1983) Epidemiological studies of diabetes mellitus in Denmark: 4. Clinical characteristics of insulin-treated diabetes. Diabetologia 25:231–234CrossRefPubMed
6.
go back to reference Stumvoll M (2004) Control of glycaemia: from molecules to men. Minkowski Lecture 2003. Diabetologia 47:770–781CrossRefPubMed Stumvoll M (2004) Control of glycaemia: from molecules to men. Minkowski Lecture 2003. Diabetologia 47:770–781CrossRefPubMed
7.
go back to reference Gottsater A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G (1993) Beta-cell function in relation to islet cell antibodies during the first three years after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 16:902–910PubMed Gottsater A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G (1993) Beta-cell function in relation to islet cell antibodies during the first three years after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 16:902–910PubMed
8.
9.
go back to reference Kockum I, Lernmark A, Dahlquist G et al (1996) Genetic and immunological findings in patients with newly diagnosed insulin-dependent diabetes mellitus. The Swedish Childhood Diabetes Study Group and the Diabetes Incidence in Sweden Study (DISS) Group. Horm Metab Res 28:344–347PubMed Kockum I, Lernmark A, Dahlquist G et al (1996) Genetic and immunological findings in patients with newly diagnosed insulin-dependent diabetes mellitus. The Swedish Childhood Diabetes Study Group and the Diabetes Incidence in Sweden Study (DISS) Group. Horm Metab Res 28:344–347PubMed
10.
go back to reference Lendrum R, Walker G, Cudworth AG et al (1976) Islet cell antibodies in diabetes mellitus. Lancet 2:1273–1276CrossRefPubMed Lendrum R, Walker G, Cudworth AG et al (1976) Islet cell antibodies in diabetes mellitus. Lancet 2:1273–1276CrossRefPubMed
11.
go back to reference Irvine WJ, Gray RS, McCallum CJ (1976) Pancreatic islet-cell antibody as a marker of asymptomatic and latent diabetes and prediabetes. Lancet 2:1097–1102CrossRefPubMed Irvine WJ, Gray RS, McCallum CJ (1976) Pancreatic islet-cell antibody as a marker of asymptomatic and latent diabetes and prediabetes. Lancet 2:1097–1102CrossRefPubMed
12.
go back to reference Groop LC, Bottazzo GF, Doniach D (1986) Islet cell antibodies identify latent Type 1 diabetes in patients aged 35–75 years at diagnosis. Diabetes 35:237–241PubMed Groop LC, Bottazzo GF, Doniach D (1986) Islet cell antibodies identify latent Type 1 diabetes in patients aged 35–75 years at diagnosis. Diabetes 35:237–241PubMed
13.
go back to reference Tuomi T, Groop LC, Zimmet P, Rowley MJ, Knowles W, Mackay IR (1993) Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359–362PubMed Tuomi T, Groop LC, Zimmet P, Rowley MJ, Knowles W, Mackay IR (1993) Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359–362PubMed
14.
go back to reference Turner RC, Stratton I, Horton V et al (1997) UKPDS 25: autoantibodies to islet cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350:1288–1293CrossRefPubMed Turner RC, Stratton I, Horton V et al (1997) UKPDS 25: autoantibodies to islet cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350:1288–1293CrossRefPubMed
15.
go back to reference Bingley PJ, Bonifacio E, Gale EAM (1999) Predicting type 1 diabetes. In: Marshall SM, Home PD, Rizza RA (eds) Diabetes Annual/12. Elsevier, Amsterdam, pp 1–20 Bingley PJ, Bonifacio E, Gale EAM (1999) Predicting type 1 diabetes. In: Marshall SM, Home PD, Rizza RA (eds) Diabetes Annual/12. Elsevier, Amsterdam, pp 1–20
16.
go back to reference Bingley PJ, Bonifacio E, Williams AJK, Genovese S, Bottazzo GF, Gale EAM (1997) Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 46:1701–1710PubMed Bingley PJ, Bonifacio E, Williams AJK, Genovese S, Bottazzo GF, Gale EAM (1997) Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 46:1701–1710PubMed
17.
go back to reference Tuomi T, Carlsson AL, Li H et al (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150–157PubMed Tuomi T, Carlsson AL, Li H et al (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150–157PubMed
18.
go back to reference Decochez K, Tits J, Coolens J-L et al (2000) High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. Diabetes Care 23:838–844PubMed Decochez K, Tits J, Coolens J-L et al (2000) High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. Diabetes Care 23:838–844PubMed
19.
go back to reference Gigerenzer G (2002) Calculated risks. How to know when numbers deceive you. Simon and Schuster, New York Gigerenzer G (2002) Calculated risks. How to know when numbers deceive you. Simon and Schuster, New York
20.
go back to reference Kobayashi T, Makanishi K, Murase T, Kosaka K (1996) Small doses of subcutaneous insulin as a strategy for preventing slowly progressive β-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45:622–626PubMed Kobayashi T, Makanishi K, Murase T, Kosaka K (1996) Small doses of subcutaneous insulin as a strategy for preventing slowly progressive β-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45:622–626PubMed
21.
go back to reference Davis TME, Wright AD, Mehta ZM et al (2005) Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 48:695–702CrossRefPubMed Davis TME, Wright AD, Mehta ZM et al (2005) Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 48:695–702CrossRefPubMed
Metadata
Title
Latent autoimmune diabetes in adults: a guide for the perplexed
Author
E. A. M. Gale
Publication date
01-11-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 11/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1954-5

Other articles of this Issue 11/2005

Diabetologia 11/2005 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.